The global mycoplasma testing market size was estimated at USD 1.03 billion in 2024 and is expected to reach USD 2.81 billion in 2033, growing at a CAGR of 11.94% from 2025 to 2033. One of the key factors driving this growth is the rising investment in research and development (R&D) across the life sciences sector, which emphasizes the need for accurate and reliable mycoplasma testing to ensure the safety and efficacy of biological products.

Pharmaceutical companies are dedicating substantial resources to the development of biopharmaceuticals and biosimilars, which require stringent contamination control to maintain product quality. For example, Bristol-Myers Squibb has invested heavily in the production of investigational medicines to support its expanding clinical trial portfolio, demonstrating the industry’s focus on rigorous testing protocols to meet regulatory standards.

The biopharmaceutical and related industries have not been significantly impacted by the COVID-19 pandemic compared to other sectors. A study published in May 2022 highlighted a correlation between mycoplasma testing trends and COVID-19-related Non-Pharmaceutical Interventions (NPIs). The study specifically examined the incidence of Mycoplasma pneumoniae following the implementation of NPIs during the pandemic. The results showed a noticeable decrease in M. pneumoniae detection globally between March 2020 and March 2021. This reduction is largely attributed to restricted transmission of the pathogen due to social distancing, mask-wearing, and other preventive measures, which led to a significant decline in M. pneumoniae infections worldwide.

Key Market Trends & Insights:

• The North America mycoplasma testing market dominated the global industry in 2024, accounting for the largest revenue share of 40.52%. This strong position is driven by the region’s well-established life sciences infrastructure, high adoption of advanced testing technologies, and significant investment in biopharmaceutical research and development.

• Within North America, the U.S. led the market and captured the largest revenue share in 2024. The country’s dominance is supported by the presence of major pharmaceutical and biotechnology companies, extensive clinical research activities, and stringent regulatory standards that emphasize contamination control and quality assurance in biological products.

• By product type, the kits and reagents segment dominated the global mycoplasma testing market in 2024, accounting for the largest revenue share of 55.72%. These kits and reagents are essential for efficient, accurate, and standardized testing, making them widely adopted across research laboratories, pharmaceutical companies, and biopharmaceutical manufacturing facilities.

• In terms of technology, the PCR (Polymerase Chain Reaction) segment held the largest revenue share of 47.14% in 2024. PCR-based mycoplasma testing is favored for its high sensitivity, specificity, and rapid turnaround, making it a preferred choice for contamination detection and quality control in cell cultures and biopharmaceutical production.

• Regarding application, the cell line testing segment accounted for the largest revenue share of 40.99% in 2024. Cell line testing is critical for ensuring the purity and safety of biological products, as contaminated cell lines can compromise research outcomes and the development of therapeutic products. This segment’s prominence highlights the importance of mycoplasma testing in maintaining the integrity of cell-based research and biopharmaceutical manufacturing processes.

Order a free sample PDF of the Mycoplasma Testing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 1.03 Billion

• 2033 Projected Market Size: USD 2.81 Billion

• CAGR (2025-2033): 11.94%

• North America: Largest Market in 2024

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Key players in the global mycoplasma testing market are actively implementing a variety of strategic initiatives to strengthen their market presence and remain competitive. These strategies include forming partnerships, pursuing mergers and acquisitions, expanding into new geographic regions, and engaging in strategic collaborations with other industry stakeholders. Such initiatives enable companies to broaden their product portfolios, access new customer segments, and enhance their technological capabilities.

Major companies operating in this market include Charles River Laboratories, Merck KGaA, Lonza Group, and Thermo Fisher Scientific. These organizations provide a comprehensive range of mycoplasma detection kits and services designed to meet the stringent requirements of biopharmaceutical research, development, and production. They leverage advanced technologies, including Polymerase Chain Reaction (PCR), Enzyme-Linked Immunosorbent Assay (ELISA), and Next-Generation Sequencing (NGS), to deliver high-precision, reliable, and rapid testing solutions for detecting mycoplasma contamination. These technological innovations, combined with strategic market initiatives, enable these companies to maintain leadership positions in the growing mycoplasma testing market.

Key Players

• Thermo Fisher Scientific, Inc.

• Merck & Co., Inc.

• Lonza Group AG

• Charles River Laboratories International, Inc.

• PromoCell GmbH

• Asahi Kasei Medical Co., Ltd.

• Sartorius AG

• InvivoGen

• Eurofins Scientific

• (ATCC) American Type Culture Collection

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The mycoplasma testing market is expected to expand steadily as the demand for reliable contamination detection in biopharmaceutical and life science research continues to grow. This expansion is supported by increasing investments in research and development, the rise of biologics and vaccine production, and ongoing innovations in detection technologies. Additionally, stringent quality control requirements and regulatory standards in pharmaceutical and biotechnology sectors are reinforcing the need for effective mycoplasma testing solutions, which is driving sustained market growth.